Slowing Biopharmaceuticals Puts A Dent In Sandoz’ Sales
Executive Summary
Slower sales growth by its Biopharmaceuticals unit amid competitive pressures in the US, combined with weakness in its Retail Generics and Anti-Infectives franchises, led Sandoz to report an overall 8% sales slide in the first quarter of this year.
You may also be interested in...
Top US Generics Players Thwarted On August At-Risk Launch Of Fingolimod
Difficulties around damages, fears over first-dose observations and criticism of invalidity challenges all contributed to a US district court judge issuing a preliminary injunction to stop leading generics players launching rivals to Novartis’ Gilenya fingolimod multiple sclerosis brand after the molecule patent expires in August this year.
Aurobindo Upbeat On Outlook As It Moves To Close Sandoz Deal
India's Aurobindo says it is betting its $1bn purchase of Sandoz' US dermatology assets will help “really fuel growth” and that the company's biggest acquisition should be wrapped up in eight to 12 weeks.
Aurobindo Expects Sandoz Business To Over-Perform
Aurobindo is betting that its $1bn purchase of Sandoz’ US assets will beat its earlier expectations and help to fuel significant growth for the Indian firm. It expects the acquisition, the company’s biggest ever, to close within 8-12 weeks.